Literature DB >> 8779143

Lung bioavailability of generic and innovator salbutamol metered dose inhalers.

D J Clark1, J Gordon-Smith, G McPhate, G Clark, B J Lipworth.   

Abstract

BACKGROUND: The aim of this study was to determine whether significant differences exist in lung bioavailability between generic (Salamol, Salbulin) and innovator (Ventolin) formulations of inhaled salbutamol given by metered dose inhalers.
METHODS: Ten healthy volunteers of mean age 20.5 years with a forced expiratory volume in one second (FEV1) of 112.1% predicted were studied in a randomised double blind single dosing crossover study. Salbutamol, 1200 micrograms, was given with mouth rinsing and lung bioavailability was assessed by measuring plasma salbutamol levels and urine excretion of salbutamol.
RESULTS: No differences were seen between innovator and generic salbutamol metered dose inhalers in plasma salbutamol levels, urinary salbutamol excretion, or extrapulmonary beta 2 activity. The maximum plasma salbutamol concentration (mean Cmax) and time to maximum concentration (median Tmax) were: Ventolin (2.93 ng/ml, 10 minutes), Salbulin (3.01 ng/ml, 10 minutes), Salamol (3.33 ng/ml, 10 minutes). The geometric mean ratio and 95% confidence interval for Cmax were: Salbulin/Ventolin 1.02 (0.69 to 1.41) and Salamol/Ventolin 1.13 (0.94 to 1.35).
CONCLUSIONS: No differences are apparent between the two generic and innovator formulations of salbutamol metered dose inhaler in terms of lung bioavailability.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8779143      PMCID: PMC1090651          DOI: 10.1136/thx.51.3.325

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.

Authors:  B J Lipworth; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; T A Moreland; A D Struthers; G A Clark; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  A comparative bronchodilator study of salbutamol and salbutamol sulphate that were administered by metered-dose inhalers.

Authors:  R E Ruffin; K M Latimer; A J Crockett; M M Blight
Journal:  Med J Aust       Date:  1989-03-06       Impact factor: 7.738

6.  Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").

Authors:  D M Newnham; B J Lipworth
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

7.  Volumatic usage: some generic salbutamol metered dose inhalers can be used.

Authors:  J K Chege; H Chrystyn
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

  7 in total
  7 in total

Review 1.  Discriminating measures of bronchodilator drug efficacy and potency.

Authors:  H Buck; M Parry-Billings
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 2.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

3.  Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

4.  Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

5.  Effects of airway calibre on lung delivery of nebulised salbutamol.

Authors:  B J Lipworth; D J Clark
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

6.  Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol.

Authors:  S J Fowler; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

7.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.